Search Results

Ceapro Inc. announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Ceapro Inc. today announced financial results and operational highlights for the first quarter ended March 31, 2024.

Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce the successful completion and closing of their all-stock merger of equals transaction, which was previously announced by Aeterna and Ceapro in their joint press release of December 14, 2023.

Aeterna Zentaris Inc. announces that it has finalized certain details regarding the previously announced merger of equals transaction (the “ Transaction ”) with Ceapro Inc. (“ Ceapro ”).

Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce that the Court of King’s Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction.

Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction at their respective special meetings.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2023.

Ceapro Inc., provided an update on its progress across its current business.

Ceapro Inc.  (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”) announced today the initiation of its Phase 1 study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation.

Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) today announced the commencement of patient dosing in its Phase 1-2a study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation.